ARIAD Pharmaceuticals, Inc.
http://www.ariad.com
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ARIAD Pharmaceuticals, Inc.
Gilead Summits Takeback Of Trodelvy Rights In Deal With Everest
Deal Snapshot: Through subsidiary Immunomedics, Gilead will pay $280m up front to gain the remaining global rights to the drug, at a time when Everest’s business model has encountered some difficulties in China.
Keeping Track: Enhertu Brings Anti-HER2 Therapy To Lung Cancer; Novaliq Platform Supports Two Dry Eye NDAs
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Gilead’s Trodelvy Wins In TROPiCS-02, But Commercial Headwinds Remain
Analysts said that while the Phase III survival data could lead to Trodelvy’s FDA approval, it still could face competitive headwinds from AstraZeneca/Daiichi Sankyo’s Enhertu.
Daiichi Sankyo/AstraZeneca Get Two Lucky Breaks For Enhertu
The FDA granted accelerated approval for the small but significant HER2-mutated NSCLC indication, while the arbitrator in Seagen’s arbitration case ruled in Daiichi Sankyo’s favor.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals